IRCT20161103030680N9 IRCT 2018-03-02 Shahed University Citaloparam in migraine prophylaxsis citalopram and migraine Evaluation of citalopram efficacy in prevention of migraine headaches 2010-03-20 anticipated 226 Complete https://irct.ir/trial/24298 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: All patients referred to Mostafa Khomeini neurology clinic who fulfilled criteria for study at first are marked by a number an then assigned in two intervention and control groups alternatively by chart of random numbers. Selection of patient for first group is by lottery, Blinding description: All drugs and placebos are put in packages with the same shapes and dimensions and after code assignment the main researchers and students receive them. They are not aware of the package contents. Researchers are not aware of patients group. The study design is explained truly for each patient separately and notify that selection of group is randomly without their awareness. 2-3 Condition 1: Migraine headaches. Condition 2: Migraine headaches. Intervention 1: patients in this group take Citalopram thirty milligrams at noon for two months. Dose escalation is gradually within two weeks. Intervention 2: Cotrol group: Patients take placebo which is provided with the same feature and weight at noon. Duration of treatment is two months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no certainty in ethical aspect from patient view.